OA
CRL icon

Operose Advisors’s Charles River Laboratories CRL Stock Holding History

Operose Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-115
Closed -$22.7K – 475
2024
Q3 		$22.7K Hold
115
– – 0.01% 383
2024
Q2 		$23.8K Hold
115
– – 0.01% 333
2024
Q1 		$31.2K Hold
115
– – 0.01% 314
2023
Q4 		$27.2K Sell
115
-98
-46% -$19.3K 0.01% 311
2023
Q3 		$41.7K Buy
+213
New +$43.7K 0.02% 341

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Operose Advisors's CRL Position: Q4 2024 in Review

Operose Advisors sold out of Charles River Laboratories (CRL) in Q4 2024, closing a stake of 115 shares — an estimated $22.7K sold.

Operose Advisors first reported a position in CRL in Q3 2023 and held it in 5 quarters. The position peaked at $41.7K in Q3 2023. 637 funds tracked by Wall St. Rank hold CRL as of Q4 2024.

  • Operose Advisors reported no remaining Charles River Laboratories position as of Q4 2024 after selling out during the quarter.
  • Operose Advisors sold 115 Charles River Laboratories shares in Q4 2024, an estimated $22.7K.
  • Operose Advisors first reported a position in Charles River Laboratories in Q3 2023 and held it in 5 quarters.
  • Operose Advisors's Charles River Laboratories position peaked at $41.7K in Q3 2023.
  • 637 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2024.

Based on Operose Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.